Table 1. Antimicrobial drug susceptibility profile of patient’s Mycobacterium fortuitum group isolate*.
| Antimicrobial drug | MIC, μg/mL | Interpretation* |
|---|---|---|
| Amikacin | <1 | Susceptible |
| Cefoxitin | 64 | Intermediate |
| Ciprofloxacin | <0.12 | Susceptible |
| Clarithromycin | 8 | Resistant† |
| Doxycycline | >16 | Resistant |
| Imipenem | 8 | Intermediate |
| Linezolid | 2 | Susceptible |
| Moxifloxacin | <0.25 | Susceptible |
| Tigecycline | 0.12 | ‡ |
| Trimethoprim/sulfamethoxazole | 1/19 | Susceptible |
| Tobramycin | >16 | Resistant |
*According to breakpoints defined by the Clinical and Laboratory Standards Institute (2). †Clarithromycin MIC after 14 d of incubation. ‡No accepted breakpoints from the Clinical and Laboratory Standards Institute exist for tigecycline.